Zimbabwe has declined a major US healthcare agreement worth $367m (£272m) over five years over Washington's request for confidential data.
The decision became public following a government memo from December was leaked, revealing that President Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official spokesperson has since explained that the US was demanding access to health data for research and commercial gain while was unwilling to guarantee the benefits from future vaccines.
"We must now begin the difficult and regrettable process of winding down our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged continued talks to secure a deal agreeable to all parties so the nation's critical HIV treatment initiative can continue.
Wider Background
This development comes after a similar situation in neighbouring Kenya, where a court blocked a related deal with the US following legal challenges were raised about the security of citizens' health data.
After resuming the presidency recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was seeking government-to-government deals to enhance openness and accountability.
Based on statements, 16 African countries have to date signed these new agreements, representing more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership could have provided immense advantages for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment through US-supported programmes," Tremont said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to surrender its genetic material and health information for a long time, with no equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that might result from that shared data," Mangwana explained.
"In essence, our nation would supply the basic resources for scientific discovery with no certainty that the resulting innovations would be available to our people should a future disease outbreak emerge."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were undermining structures previously set up through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to deal with potential pandemics.
"This system is intended to ensure that when a nation contributes its information, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to develop them."
These objections regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage ongoing discussions with our American counterparts on how future collaboration could be structured in a way that respects the sovereignty and interests of both nations."
Health Experts Reaction
A leading public health body expressed it acknowledged the official position, but suggested that negotiations need to persist considering a large portion of the nation's Aids initiatives were funded by external financing.
"In cases where technical issues arise, including those relating to data governance or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," the group said.
The halted deal highlights the ongoing tensions between receiving much-needed international aid and safeguarding local interests in an ever more data-driven world.